CD38 and acute lymphoblastic leukemia: For instance, it is known that BCR::ABL1 and TP53 mutations are almost mutually exclusive in acute lymphoblastic leukemia and, interestingly, patients with these two genetic findings in our study generally have distinct immunophenotypes: a dominant CD34+/CD38− subpopulation if BCR::ABL1 positive versus a combination of CD34+/CD38+ and CD34−/CD38+ cells if TP53 mutant.